Case Challenges in Lipid Management: PCSK9 Inhibitors in Practice
Cardiology
Curriculum:
PCSK9 Inhibitors: Where Do They Fit in the Treatment of Dyslipidemia?
PCSK9 Inhibitors: Where Do They Fit in the Treatment of Dyslipidemia?
Credits:
1.5 AMA PRA Category 1 Credit(s) ™
1.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
April 07, 2016
April 07, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Primary Care Physicians; Nurse Practitioners; Physician Assistants
Relevant Terms:
Lipid management; cardiovascular disease; athersclerosis; familial hypercholesterolemia; dyslipidemia
Christopher Paul Cannon, MD
Christopher Paul Cannon, MD
Executive Director, Cardiometabolic Trials,
Harvard Clinical Research Institute
Cardiovascular Division, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School
Boston, MA
Bio
Dr. Cannon is a professor of medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital.
Dr. Cannon has published over 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 17 books. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association.
As a senior investigator of the TIMI Study Group, he has been principal investigator of more than 15 multicenter clinical trials, including TACTICS-TIMI 18 and PROVE IT, and the IMPROVE IT trial. Dr. Cannon now serves as Executive Director of Cardiometabolic Trials at the Harvard Clinical Research Institute (HCRI). He is leading the RE-DUAL PCI trial, studying novel anticoagulant strategies in patients with atrial fibrillation undergoing stenting, and collaborates on many other trials and registry projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids and prevention.
Ty J. Gluckman, MD, FACC, FAHA
Ty J. Gluckman, MD, FACC, FAHA
Medical Director, Clinical Excellence
Providence Heart and Vascular Institute, Oregon Region
Portland, Oregon
Bio
Dr. Ty J. Gluckman is Director of Clinical Excellence at the Heart and Vascular Institute of Providence St. Vincent Medical Center in Portland, Oregon and an adjunct member of the The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, Maryland. Dr. Gluckman graduated summa cum laude with highest honors from Brandeis University. He received his medical degree from Northwestern University Medical School and did his internal medicine training at McGaw Medical Center of Northwestern University, where he remained for additional years as chief resident and an Instructor in Medicine. He completed his cardiology fellowship training at the Johns Hopkins Hospital and served as chief fellow during his final year there. His principal clinical and research interests include the management of acute coronary syndromes, the evaluation of premature graft failure after coronary artery bypass graft surgery, and variability in responsiveness to antiplatelet agents. Dr. Gluckman serves as co-editor of the National Preventive Cardiology CME Newsletter Cardiology News and Issues in the New Millennium, which has a circulation of nearly 100,000 physicians and has recent publications in the Archives of Internal Medicine, JAMA, and the Journal of the American College of Cardiology. He is an active councilor and Director of Quality for the State of Oregon Chapter of the American College of Cardiology, a board member of the Portland Metro and SW Washington Chapter of the American Heart Association, and associate editor for clinical documents and practice guidelines for Cardiosource.
| 1. | Discuss and interpret current guideline recommendations taking into consideration the latest clinical trial data | 2. | Identify patient groups in which treatment beyond statins may be needed to optimize lipid-related CV risk |
| 3. | Outline the mechanism and potential applications for PCSK9 inhibitors in lowering LDL-C in patients with hypercholesterolemia | 4. | Summarize current clinical data for the safety and efficacy of PCSK9 inhibitors in reducing LDL-C and cardiovascular risk |
| 1. | Discuss and interpret current guideline recommendations taking into consideration the latest clinical trial data |
| 2. | Identify patient groups in which treatment beyond statins may be needed to optimize lipid-related CV risk |
| 3. | Outline the mechanism and potential applications for PCSK9 inhibitors in lowering LDL-C in patients with hypercholesterolemia |
| 4. | Summarize current clinical data for the safety and efficacy of PCSK9 inhibitors in reducing LDL-C and cardiovascular risk |
LAUNCH DATE/EXPIRATION DATE
This activity was launched on April 7, 2016 and will expire on April 7, 2017.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with dyslipidemia.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designed to meet the educational needs of primary care clinicans, NPs, PAs and other health care professionals involved in the care of patients with dyslipidemia.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO CLAIM CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.5 AMA PRA Category 1 credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
| Name of Faculty | Reported Financial Relationship |
|---|---|
| Christopher Paul Cannon, MD | Dr. Cannon has received grants from Accumetrics, Arisaph, Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Janssen, Merck, and Takeda. He has consulted for Boehringer-Ingelheim, BMS, CSL Behring, Essentialis, GlaxoSmithKline, Kowa, Merck, Takeda, Lipimedix, Pfizer, Regeneron and Sanofi. |
HORIZON PLANNER DISCLOSURES
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Brian Lee, PharmD, Cara Williams, PharmD, Elizabeth Wilkerson and their spouses do not have any relevant financial relationships within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Brian Lee, PharmD, Cara Williams, PharmD, Elizabeth Wilkerson and their spouses do not have any relevant financial relationships within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
SUPPORT ACKNOWLEDGEMENT
This educational program is being supported by independent educational grants from Sanofi U.S. and Amgen.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
